Following the diligent efforts of physicians associated with a group called Front Line Covid-19 Critical Care Alliance (FLCCC), the National Institutes of Health (NIH) has upgraded their recommendation for the “miraculous” drug ivermectin, making it an option for use in treating COVID-19 within the United States.
The result comes one week after Dr. Paul Marik and Dr. Pierre Kory—founding members of the FLCCC, along with Dr. Andrew Hill, researcher and consultant to the World Health Organization (WHO), presented their data before the NIH Treatment Guidelines Panel.
“By no longer recommending against ivermectin use,” the statement said, “doctors should feel more open in prescribing ivermectin as another therapeutic option for the treatment of COVID-19. This may clear its path towards FDA [Food and Drug Administration] emergency use approval.”
“Ivermectin is one of the world’s safest, cheapest and most widely available drugs,” explained Dr. Kory, President of the FLCCC Alliance. “The studies we presented to the NIH revealed high levels of statistical significance showing large magnitude benefit in transmission rates, need for hospitalization, and death. What’s more, the totality of trials data supporting ivermectin is without precedent.”
In its January 14 updated statement regarding the use of ivermectin, NIH indicated they will continue to evaluate additional trials as they are released.
Last month Dr. Kory and his team testified before the U.S. Senate Homeland Security Committee in favor of authorizing ivermectin, a Nobel Prize–winning anti-parasitic agent, for early treatment of the novel coronavirus. In his impassioned presentation, Dr. Kory explained that ivermectin “basically obliterates transmission of this virus,” with “miraculous effectiveness.”
No comments:
Post a Comment